Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
Status: Enrolling
Updated:  6/13/2012
University of California - San Francisco
mi
from
San Francisco, CA
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
Status: Enrolling
Updated: 6/13/2012
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
Status: Enrolling
Updated:  6/13/2012
Oregon Health and Science University
mi
from
Portland, OR
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
Status: Enrolling
Updated: 6/13/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
Status: Enrolling
Updated:  6/13/2012
Memorial Hermann Hospital, Texas Medical Center
mi
from
Houston, TX
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
Status: Enrolling
Updated: 6/13/2012
Memorial Hermann Hospital, Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Engorgement Study With a Double Electric Breast Pump
Engorgement Study With the Simplisse Double Electric Breast Pump
Status: Enrolling
Updated:  6/13/2012
Newborn Care Center Clinic
mi
from
Reno, NV
Engorgement Study With a Double Electric Breast Pump
Engorgement Study With the Simplisse Double Electric Breast Pump
Status: Enrolling
Updated: 6/13/2012
Newborn Care Center Clinic
mi
from
Reno, NV
Click here to add this to my saved trials
Platelet Function During ECMO (Extra Corporeal Membrane Oxygenation)
Platelet Function During ECMO
Status: Enrolling
Updated:  6/20/2012
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Platelet Function During ECMO (Extra Corporeal Membrane Oxygenation)
Platelet Function During ECMO
Status: Enrolling
Updated: 6/20/2012
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated:  6/22/2012
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated: 6/22/2012
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated:  6/22/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated: 6/22/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status
Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status
Status: Enrolling
Updated:  6/27/2012
Buenavista Palace Hotel and Spa
mi
from
Orlando, FL
Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status
Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status
Status: Enrolling
Updated: 6/27/2012
Buenavista Palace Hotel and Spa
mi
from
Orlando, FL
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
City of Hope
mi
from
Upper San Gabriel Valley, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
City of Hope
mi
from
Upper San Gabriel Valley, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Miller Children's Hospital
mi
from
Long Beach, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Oakland Children's Hospital
mi
from
Oakland, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Oakland Children's Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
UCSF School of Medicine
mi
from
San Francisco, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
University of Miami Cancer Center
mi
from
Miami, FL
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
University of Miami Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Childrens Memorial
mi
from
Chicago, IL
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Childrens Memorial
mi
from
Chicago, IL
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Johns Hopkins University
mi
from
Baltimore, MD
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Dana Farber
mi
from
Boston, MA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
New York University Medical Center
mi
from
New York, NY
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Nationwide Children's Hospital
mi
from
Columbus, OH
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Oregon Health and Science University
mi
from
Portland, OR
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
St. Jude
mi
from
Memphis, TN
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
St. Jude
mi
from
Memphis, TN
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Seattle Children's Hospital
mi
from
Seattle, WA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Huntsville, AL
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Anaheim, CA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Denver, CO
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
New Britain, CT
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Sarasota, FL
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Meridian, ID
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Jeffersonville, IN
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Newburg, IN
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Newburg, IN
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Shreveport, LA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Annapolis, MD
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Southaven, MS
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Southaven, MS
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Missoula, MT
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Lawrence, NJ
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Lawrence, NJ
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Albuquerque, NM
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Concord, NC
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Concord, NC
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Bismarck, ND
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
mi
from
Lancaster, PA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials